Randox launches whole pathogen Blood Borne Virus Controls at AACC
Whole pathogen Blood Borne Virus (BBV) controls have been brought to market by global diagnostics company Randox Laboratories.
The molecular controls, available under the brand name Qnostics, are versatile in monitoring the presence of BBVs, including HIV, Hepatitis B and Hepatitis C.
For use with molecular methods, the controls are manufactured using whole pathogens and therefore mimic the patient sample, providing the best sample matrix for laboratories.
Lynsey Adams, Randox Quality Control Manager, explained;
“We’re delighted to be able to bring to market these whole pathogen Blood Borne Virus Controls, which are designed to help molecular laboratories effectively manage assay performance.
“Using whole pathogens in the development of the controls ensures we meet the demands of today’s molecular diagnostics laboratories by monitoring the entire testing process.”
The Molecular BBV controls from Randox, which are liquid frozen for user convenience and ease of use, will aid microbiology and virology laboratories to monitor assay drift and ultimately will help to ensure accurate test system performance. Each control is designed to be medium positive and are suitable for use with a variety of molecular workflows.
“These versatile Blood Borne Virus controls can be used in the daily monitoring of assay performance, but are equally applicable for use in the validation/verification of new assays, and may also be used for troubleshooting after poor EQA performance.”
Randox Blood Borne Virus Molecular Controls are manufactured to ISO 13485 standards and calibrated against an independent Internal Reference Material. Also included within the Qnostics BBV range are Molecular Q panels. Each molecular Q panel includes a negative, low, medium and high positive sample designed to cover more of the assays measuring range.
Key Features and Benefits of Randox Blood Borne Virus Qnostics Controls:
- Third party controls as recommended by ISO 15189:2012
- Specifically designed to meet the demands of today’s molecular diagnostics laboratory and laboratories carrying out Nucleic Acid Testing (NAT)
- Suitable for use across a wide range of molecular assays to monitor the entire molecular workflow from extraction to amplification and detection
- Flexible and suitable for use with the majority of commercial and in-house molecular methods
- Traceable to the current relevant WHO International Standards and characterised by digital PCR
- Liquid frozen for user convenience and ease of use, with no additional preparation required
- Calibrated against an independent Internal Reference Material (IRM)
- Quality products manufactured to ISO 13485: 2016 standards
- Manufactured using whole pathogens and therefore mimic the patient sample providing the best possible sample matrix for laboratories
- New controls available include Hepatitis B (HBV) Medium Q Control, Hepatitis C (HCV) Medium Q Control and HIV Medium Q Control
- US-IVD labelled for clinical use
For further information please visit https://www.randox.com/molecular-infectious-disease-controls/blood-borne-virus-testing/, visit us at stand 1101 at this year’s AACC or email email@example.com
Randox Food Diagnostics will be attending Apimondia 2019 in Montreal, Canada from the 8th – 12th September.
Apimondia is the International Federation of Beekeepers’ Association. Its major objective is to facilitate the exchange of information and discussions within the honey industry by organising seminars where beekeepers, scientists, honey-traders, agents for development, technicians and legislators meet to listen, discuss and learn from one another.
In order to help the honey industry Randox Food Diagnostics have developed Biochip Array Technology. Biochip allows for the detection of multiple antibiotics / antimicrobials / pesticides from a single honey sample.
Antibiotics such as oxytetracycline are essential for the control of bacterial diseases of agricultural plants. Most applications are by spray treatments in orchards therefore bees collecting nectar from treated plants causes antibiotic residues to transfer to the honey.
It has previously been idenitified that antibiotic-resistant bacteria can be found in the guts of insects feeding on a variety of plants, which are not exposed to significant levels of antibiotics in other forms. K Ignasiak 2016 Insects are responsible for the pollination of most flowering plants. Importantly, insects have an economic role, as domesticated pollinators bees alone contribute between $1.6 and $5.7 billion to US agriculture alone. This exposure to antibiotic residues can cause adverse health effects in humans via honey consumption and in the long term create antibiotic resistance within the entire food chain.
Randox offer a vast number of arrays for the detection of antimicrobials in honey including: sulphonamides, trimethoprim, dapsone, Quinolones, streptomycin, tetracyclines, erythromycin, nitroimidazoles and many more. Our Biochip platform enables the user to run up to 54 honey samples on the Evidence Investigator analyser in under 2 hours 30 minutes, allowing the user to consolidate costs and time.
See our full range of arrays for the detection of antibiotics on Biochip Array Technology:
Stop by booth B1 at Apimondia to find out about the Randox Food Diagnostics range of products for the screening of antibiotics in honey.
For further information please email firstname.lastname@example.org
Global diagnostics company Randox Laboratories has unveiled an innovative new test for the risk assessment of cardiovascular disease at this year’s AACC Clinical Lab Expo in Anaheim, California. The test detects and measures the cardiac biomarker sPLA2-IIA. When raised, sPLA2-IIA is an independent indicator of primary and secondary cardiovascular risk. The release of the new automated sPLA2-IIA assay from Randox adds to the company’s extensive cardiac and lipid testing panel, that are all designed for use on biochemistry platforms.
Susan Hammond, Product Specialist, commented;
“By 2030, it is estimated that almost 23.6 million people globally will die from CVD, with heart disease and stroke projected to remain the leading causes of death. This confirms that early diagnosis is an essential step in reducing the number of individuals affected. The continued investment and addition of early biomarkers that add clinical utility in cardiac risk testing is key to refining clinical assessment, and ultimately the treatment plan required.”
sPLA2-llA, a member of the secretory phospholipase A2 family, offers clinical utility as an inflammatory biomarker specifically in the diagnosis of CVD risk. As the prototypic member of the group II sPLA2 subfamily, it is known as “inflammatory sPLA2”.
Susan Hammond continued;
“sPLA2 -llA hydrolyses phospholipids from membranes, native lipoproteins and oxidized protein. As it is not bound to Apolipoprotein B its impact is more significant. Hydrolysis produces biolipid mediators lyso phospholipids and fatty acids along with Arachidonic acid which then accelerates inflammatory mediators. Due to increases in lipid and inflammatory mediators, increased cholesterol rich foam cells form- adding to plaque formation. sPLA2-IIA reduces biomarkers such as HDL-C capacity to mediate cellular cholesterol efflux from these lipid loaded macrophages.”
Key Benefits of the Randox sPLA2-llA assay
A niche product from Randox meaning that Randox are one of the only manufacturers to provide the sPLA2-llA mass test in an automated biochemistry format.
Applications available detailing instrument-specific settings for the convenient use of the Randox sPLA2-llA assay on a wide range of clinical chemistry analysers.
Liquid ready-to-use reagents for convenience and ease-of-use.
Latex enhanced immunoturbidimetric method delivering high performance.
Dedicated controls and calibrators available offering a complete testing package.
Automated assay which removes the inconvenience and time consumption associated with traditional ELISA based testing.
For Research Use Only!
AWARE NI is the depression charity for Northern Ireland with an established network of 24 support groups in rural and urban areas across the country. They also deliver mental health and wellbeing programmes into communities, schools, colleges, universities and workplaces. Mind Your Mood is an initiative designed and managed by students at Ulster University to help break down the stigma of mental health and encourage students to access support.
Dr. Peter FitzGerald, Managing Director and Founder of Randox Laboratories, commented:
“There is no doubt that mental health issues are a major concern within our society and the vigour with which staff at Randox have fundraised for AWARE NI and Mind Your Mood, two causes close to everybody’s hearts, is to be commended.
“Randox staff across all areas – from Science to Engineering and Business to Manufacturing – have raised a substantial sum for our two charity partners and we hope that this figure will aid awareness of mental health and contribute to the help given to those suffering in Northern Ireland.”
The partnership, which was announced in July 2018, kicked off with the annual Randox Fest staff BBQ in August where 400 staff members had the opportunity to participate in a football tournament, tug-of-war and rounders. Talented musicians amongst Team Randox even took to the stage to bring live music to the festivities.
Throughout the year, Randox staff continued to enthusiastically support AWARE and Mind Your Mood. In October 2018, Randox hosted a company-wide Mental Health Month which saw various divisions take part in a fundraising coffee morning in Randox Health’s clinic in Holywood, a Wear Yellow Day across all of Randox’s NI sites, a daring abseil from the dome of Victoria Square Belfast and a fundraising bake sale for staff members.
The Randox Gaelic Football team also fundraised for the charities with their participation in an Interfirm Tournament in November 2018, while the annual Randox Christmas Raffle in December 2018 was once again popular as staff members vied for top prizes of a 55” Sony smart TV, an extra day of annual leave and tickets to the world-renowned Randox Health Grand National. Children of Randox staff also enjoyed a visit from another famous and festive figure in a red suit at this yearly family event in the staff calendar.
Clare Galbraith, Corporate Fundraising Officer for AWARE, commented:
“We have thoroughly enjoying working with Randox over the past year and are incredibly grateful to Randox staff for their hard work and perseverance in achieving this tremendous amount of fundraising.
“The vital work of AWARE is funded primarily by donations and without the generosity of people like those at Randox, we would not be able to provide the services we do to those living with depression and bipolar disorder in Northern Ireland.”
The new year in 2019 saw Randox staff taking part in a charity golf day at Galgorm Castle Golf Club, Belfast City Marathon and another abseil, this time from the top of Cave Hill’s most iconic landmark, Belfast Castle. Two brave staff members have also volunteered to scale the heights in a 10,000ft skydive in Garvagh which will take place later in the year.
Randox fundraising for AWARE NI and Mind Your Mood came to an end with AWARE NI’s Dragon Boat race on the River Lagan at the end of June 2019. Two Randox boats competed against 12 others in a race against the clock, with one Team Randox boat reaching the semi-final of the event.
Eddie Friel, Director of Development and Alumni Relations, Ulster University said:
“Ulster University and Randox have a long-standing partnership built around research, knowledge, sharing, collaboration and student opportunity. This generous sum raised by Randox staff will go a long way in helping to support the mental health activity taking place at our four campuses through the Mind Your Mood initiative.”
Over £14,000 was raised, £10,826 of which was for AWARE NI-related activities and £3,270 for Mind Your Mood.
For further information please email email@example.com or phone 028 9442 2413.
Randox Quality Control is set to launch new Acusera Verify linearity sets at the American Association for Clinical Chemistry 2019.
Randox Linearity sets are designed to challenge a larger segment of an instrument’s reportable range, and test validity of system calibration. The Acusera Verify materials will cover testing of C-reactive Protein, Rheumatoid Factor, Lipids, Therapeutic Drugs, and Esoterics, amongst others and are compatible for use with Roche Cobas and Beckman systems.
Materials also include a unique combination of analytes, meaning laboratories do not need multiple products for testing, which reduces both costs and need for storage space.
Lynsey Adams, Randox Quality Control Manager, commented;
“Acusera Verify’s range of instrument-dedicated calibration verifiers are designed to challenge the entire Analytical Measuring Range, whilst remaining convenient to use and helping to meet Clinical Laboratory Improvement Amendments (CLIA) requirements.”
According to CLIA, a laboratory should perform and document calibration verification procedures at least once every 6 months and/or whenever one of the following occur;
- A complete change of reagents for a procedure is introduced, unless the laboratory can demonstrate that changing reagent lot numbers does not affect the range.
- There is a major preventive maintenance or replacement of critical parts that may influence test performance.
- Control material reflects an unusual trend or shift, or are outside of the laboratory’s acceptable limits, and other means of assessing and correcting unacceptable control values fail to identify and correct the problem.
- Laboratory’s established schedule for verifying the reportable range for patient test results requires more frequent calibration verification.
- New instrument validation.
CLIA also recommends that a minimum of 3 levels are tested covering the low end, mid-point and high end of the reportable range. The Clinical and Laboratory Standards Institute (CLSI) however, recommend at least 5 levels are tested. It is also considered best practice that laboratories run at least 3 replicates of each level in the same way they would a patient or control sample.
Acusera Verify from Randox QC will ensure that laboratories meet the recommended CLIA and CLSI guidelines in both a timely and costly manner.
Randox Linearity sets available:
- C-Reactive Protein (CRP) Linearity Verifiers
- High Sensitivity C-Reactive Protein (hsCRP) Linearity Verifier
- Esoterics Linearity Verifier
- Rheumatoid Factor (RF) Linearity Verifier
- Lipids Linearity Verifier
- Apolipoprotein A1 (Apo A1) & Apolipoprotein B (Apo B) Linearity Verifier
- Therapeutic Drug Monitoring (TDM) Linearity Verifier
- CO2 and Electrolytes Linearity Verifier
Acusera Verify also allows users to access real-time peer group data and automatically-generated statistics through a cloud-based data reduction software package which is supplied with all linearity sets. This provides laboratories with comprehensive graphs of results and at-a-glance performance assessment.
Global diagnostics firm Randox will next month showcase its unique life science capabilities in areas including Stroke differentiation and quality control for a range of infectious diseases, at the world’s largest laboratory medicine conference – the AACC Annual Scientific Meeting & Clinical Lab Expo – in California.
The 71st event from the American Association for Clinical Chemistry (AACC) is set to highlight the best in the industry on the world stage once again as clinicians, companies and customers from all over the world flock to the Californian Anaheim Convention Centre from Sunday 4th to Thursday 8th August 2019.
“We look forward to AACC every year as we exhibit our constantly-evolving revolutionary technologies,” said Randox Managing Director, Dr. Peter FitzGerald.
“This year we will once again highlight Randox’s ground-breaking diagnostic products and services which help to save and extend lives across the world.”
Launching at this year’s AACC event are a number of exciting new innovations from Randox, including a new offering of Infectious Disease Serology Internal Quality Controls which includes quality control material vital for the testing of HIV, Hepatitis A, Congenital infections and even Lyme Disease.
Dr. FitzGerald continued;
“We are delighted to bring our Infectious Disease Serology Internal Quality Control portfolio to market for the first time. There are approximately 1 million people in the US living with HIV and around 15% unaware they are infected.
“The impact of all infectious diseases, including HIV, is increasing and, therefore, laboratories play an increasingly larger role in providing accurate results. This is a key component in controlling the spread of infection.”
At AACC Randox will also be unveiling its brand new Randox Stroke Biochip, an advancement of its Biochip Array Technology in which an investment of £305 million has been invested to date. This disruptive technology is set to enhance CT scanning technology to facilitate accurate classification of stroke patients and improve patient care pathways.
Dr FitzGerald added;
“We are pleased to highlight our brand new Randox Stroke Biochip which is set to revolutionise stroke differentiation when time is of the essence. There is great tragedy in the fact that the majority of stroke damage can be minimised if intervention is delivered on time.
“Our stroke test is the vital next step – assisting clinicians in making a rapid diagnosis and differentiation between haemorrhagic and ischaemic stroke, so their patients get the right treatment at the right time.”
Randox look forward to showcasing the latest innovations in diagnostic capabilities at AACC 2019 as they strive to attain earlier diagnoses and, subsequently, earlier treatment and intervention which will directly impact on positive outcomes and reduce the burden on healthcare services. From Stroke and HIV to Lyme Disease and Hepatitis A virus, the company’s innovative technologies facilitate improved prognosis for patients when it matters most.
AACC runs from the 4th to the 8th of August 2019 at Anaheim Convention Centre, Anaheim, California. Randox can be found at booth #1101.
Bile acids are water-soluble, amphipathic end products of cholesterol metabolism and are involved in liver, biliary and intestinal diseases. They are formed in the liver and are absorbed in the small intestine before being excreted. The fundamental role of bile acids is to aid in the digestion and absorption of fats and fat-soluble vitamins in the small intestine.1
Intrahepatic Cholestasis of Pregnancy
Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-specific liver disorder. It can be indicated by pruritus, jaundice, elevated total bile acids and/or serum transaminases and usually affects women during the second and third trimester of pregnancy.2,3
Intrahepatic Cholestasis of pregnancy or Obstetric Cholestasis is a condition that restricts the flow of bile through the gallbladder resulting in a build-up of bile acids in the liver.3 Due to the build-up, bile acids leak into the bloodstream where they are detected at concerning levels. It is an extremely serious complication of pregnancy that can lead to the increased risk of premature birth or even stillbirth, as such it is vital that women with the disease are monitored carefully.
In healthy pregnancies, there is very little increase in total bile acid levels although a slight increase is likely to be seen in the third trimester. Measurement of total bile acids in serum is thought to be the most suitable method of diagnosing and monitoring ICP.6
According to several reports total bile acid levels in ICP can reach as high as 100 times the upper limit of a normal pregnancy. It has been reported that a doubling in maternal serum bile acids, results in a 200% increased risk of stillbirth with total bile acids thought to trigger the onset of preterm labour. Additionally, bile acids can affect the foetal cardiovascular system as it has been found that there are often cardiac rhythm disturbances in the foetus due to the elevated bile acids in circulation.5
Although it is a rare condition, with only 0.3-0.5% of women likely to develop ICP, it can have extreme risks and so it is important to properly diagnose and monitor the condition.6 ICP increases the risk of meconium staining of the amniotic fluid and is reported to be a sign of foetal distress. This complication is found in 16-58% of all ICP cases, worryingly 100% of cases have resulted in foetal death. The frequency of this condition is found to be greater in pregnancies with higher levels of serum total bile acids.
There are several risk factors associated with ICP such as a family history of ICP, use of oral contraceptives, assisted reproduction techniques and multiple gestation. Genetic influence accounts for approximately 15% of ICP cases. Dietary selenium is a contributing environmental factor as serum selenium levels often decrease throughout pregnancy. Further to this, incidences of ICP rise in the winter months, most likely due to the fact selenium levels are naturally less during these months.7,8
Total Bile Acids
In addition to ICP, bile acid levels are also measured in the diagnosis of other liver disorders. The bile acids test in an extremely sensitive indicator of liver function, capable of detecting changes in hepatic function before clinical symptoms arise, thus providing valuable information that standard liver function tests cannot. As a result of its high sensitivity, bile acids can be used to assess liver function in transplant patients, allowing monitoring of the transplant success and of antirejection therapy. The bile acids test is most beneficial when used in conjunction with standard liver function tests such as ALT and AST which are markers of liver damage rather than liver function.
Measurement of Total Bile Acids
The enzyme cycling method, also known as the Fifth Generation Bile Acids test, is a method that allows for signal amplification through cycled regeneration reactions as can be seen in Figure 1. In the presence of Thio-NAD, the enzyme 3-α hydroxysteroid dehydrogenase (3-α HSD) converts bile acids to 3-keto steroids and Thio-NADH. The reaction is reversible and 3-α HSD can convert 3-keto steroids and Thio-NADH to bile acids and Thio-NAD. In the presence of excess NADH, the enzyme cycling occurs efficiently and the rate of formation of Thio-NADH is determined by measuring specific change of absorbance at 405 nm and is proportional to the amount of total bile acids in the sample. The analysing capability of the fifth generation total bile acids assay is far beyond the performance of conventional bile acid tests.10,11
Figure 1: The assay principle⁹
Inadequacies of Traditional Bile Acids Assays
Determining the cause and extent of liver damage is important in guiding treatment decisions and preventing disease progression. Standard liver function tests include; ALT, AST, ALP, GGT and Bilirubin. The measurement of TBA is most beneficial in conjunction with these standard liver tests and offers unrivalled sensitivity allowing identification of early stage liver dysfunction. There are several commercial methods available for the detection and measurement of TBA in serum. Traditional TBA tests based on the enzymatic method use nitrotetrazolium blue (NBT) to form a formazan dye. The reaction is measured at 546nm and the intensity of the colour is proportional to the concentration of bile acids.
Newer methods such as the enzyme cycling method or fifth generation methods offer many advantages including greater sensitivity, liquid reagents, small sample volumes and reduced instrument contamination from formazan dye. Additionally, the fifth generation assay does not suffer from interference from lipaemic or haemolytic samples. Both lipemia and haemolysis are common in new-borns and pregnant women, so this further supports that the fifth generation test is more sensitive for these sample types.12
Want to know more?
Contact us or download our total bile acids whitepaper
Reagents Resource Hub
High Performance & Unique Testing
 The continuing importance of bile acids in liver and intestinal disease. A.f., Hofmann. 1999, Arch Intern Med, pp. 2647-2658.
 Diagnostic and Therapeutic Profiles of Serum Bile Acids in Women with Intrahepatic Cholestasis of Pregnancy – A Pseudo-Targeted Metabolomics Study. Cui, Yue. Xu, Biao. Zhang, Xiaoqing. He, Yifan. Shao, Yong. Ding, Min. s.l. : Clinica Chimica, 2018, Vol. 483.
 Randox Laboratories. Bile Acids Test for Obstetric Cholestasis – A serious complication of pregnancy. 2012.
 British Liver Trust (2019) Facts about Liver Disease, Available at: https://www.britishlivertrust.org.uk/about-us/media-centre/facts-about-liver-disease/ (Accessed: 18th June 2019).
 .Geenes, Victoria. Williamson, Catherine. 17, s.l. : World J Gastroenterol, 2009, Vol. 15.
 Howland, Genevieve. Cholestasis of Pregnancy: Why You Can’t Ditch the Itch. Mama Natural. [Online] December 22, 2018. [Cited: February 19, 2019.] https://www.mamanatural.com/cholestasis-of-pregnancy/.
 Bile Acid Levels and Risk of Adverse Perinatal Outcomes in Intrahepatic Cholestasis of Pregnancy: A Meta-Analysis. Cui, Donghua, et al.
 Intrahepatic Cholestasis of Pregnancy. Chivers, Sian. Williamson, Catherine. 7, 2018, Vol. 28.
 Masoud, N; Neill, S.H. Serum bile acids as a sensitive biological marker for evaluating hepatic effects of organic solvents. Available from URL: https://www.ncbi.nlm.nih.gov/pubmed/23885947 [Accessed 1 November 2018]
 Microassay of Serum Bile Acids by an Enzymatic Cycling Method. Komiyama, Y, et al. 10, s.l. : Chemical and Pharmaceutical Bulletin, 1982, Vol. 30.
 Evaluation of a Colorimetric Enzymatic Procedure for Determining the Total Bile Acids in the Blood. Agape, V, et al. 3, s.l. : Minerva Gastroenterologica e Dietologica, 1989, Vol. 35.
 Total Bile Acids Test & Clinical Diagnosis. Diazyme. 2019.
Scotland is set to introduce a new “zero tolerance” policy to those caught driving under the influence of drugs.
Ministers in Scotland want to make it easier for police officers to target people driving with illegal drugs in their bloodstream. The policy will supersede the current need to prove that someone was driving in an impaired manner as a result of drug consumption. The law in Scotland currently states that it is illegal to drive if impaired by drugs, be it prescription or illegal drugs.
Justice Secretary Humza Yousaf said;
“The introduction of drug driving limits will strengthen the power of Scotland’s police and prosecutors to tackle the minority of drivers who irresponsibly put themselves and other road-users at risk. Drug driving is completely unacceptable, and we will continue to use all of the tools at our disposal to prevent the avoidable deaths and damage caused by those who drive under the influence of drugs. Together with our stringent drink-driving limits, these new laws will ensure that Scotland have the UK’s most robust laws against impaired and unsafe driving.”
Under the new plan, eight of the most commonly abuse illegal drugs – including heroin, ketamine and ecstasy – will have limits set very close to zero to rule out claims of accidental exposure. A further eight drugs, which can have medicinal purposes – such as diazepam and methadone – will have higher limits based on their ability to impair drivers. These proposals would mean just having drugs in your system that breach the limits, this is sufficient evidence to prosecute.
Utilising our Biochip Array Technology, the Evidence MultiSTAT From Randox Toxicology has screening panels which cover a broad range of classical, prescription and common DUID drugs of abuse.
A host of family-friendly country fun will descend on the majestic setting of Shane’s Castle on Saturday 27th July as Randox Antrim Show comes to town.
The event offers an enjoyable day out in the country as the best horses, cattle, sheep, fruit, vegetables, craftwork and baked goods are brought to one location for a public showcase. It also involves children’s entertainment, dog agility displays, a petting zoo, live music, sheep shearing, and stalls, to name just a few of the things made possible by the support of many sponsors, including that from Antrim and Newtownabbey Borough Council.
In the ‘Festival of Food’ marquee local produce will be promoted by celebrity chef Paula McIntryre and local chef Jonny Clarke from The Holestone, Parkgate, who will be hosting cookery demonstrations throughout the day. They’ll be joined by local food producers keen for the public to sample their wares.
The show is indebted to the Northern Ireland Regional Food Programme for providing sponsorship in this area, which has also enabled, in conjunction with the McKeever Hotel Group, a schools’ competition to promote local produce. The top three entrants in the primary and secondary sections receive complimentary access to the event to discover who won.
Randox Antrim Show is an event where children and pets are welcome. The popular Children’s Pet Show accepts £1 entries from U16s on the day, just ahead of the 1.30pm judging in the cattle ring with the ‘Pet Show’ sign. Note, large animals may be refused entry for health and safety reasons. A free Children’s Treasure Hunt for U12s has also recently been introduced.
The entertainment marquee is home to live music and the jiving competition that annually crowns the Show’s ‘King & Queen of the Castle.’ The show’s entertainment is made possible by support from the Enkalon Foundation. For the winning jiving couple there is a cash prize of £200 on offer, £100 for second and £50 for third place. Entries are taken on the day of the show.
In the Horticulture and Home Industries section, as well as a new ‘Jim McKay Trophy’ for best exhibitor in the vegetable section, there is a new Young Farmers’ Clubs Craft class to make a ‘Kitchen Memo Board’. The section includes a range of new classes including some in Photography.
As one of Northern Ireland’s leading regional one-day agricultural shows, Antrim is delighted to be hosting four Northern Ireland championships in its cattle section: The Thompson’s NISA Dairy Cow Championship; the Aberdeen Angus Ulster Championship; the Dexter Group’s Premier Show; and the Northern Ireland Limousin Championship.
Visit the show’s website for the full schedule and ultimate close date for entries, however, entries for the horticulture section are still accepted up until Friday 26 July by contacting that section direct on 075 2609 9966. Only show jumping classes (and in exceptional circumstances other equine classes) can be entered on the day of the Show. For enquiries email firstname.lastname@example.org.
Randox Antrim Show takes place on Saturday 27 July at Shanes Castle, from 9am until 5pm. Admission at the gate is £10 per Adult, £5 per Youth (12-17 years), YFC member is £5 by showing card, and Under 12s go free when accompanied by a paying adult. Car parking is free. Discounted Adult tickets are available only in advance until 25 July on the show website.
For further information about the Randox Antrim Show please contact the Randox PR team by emailing email@example.com or phoning 028 9442 2413.
For our 2018/19 placement students, their year with Randox is almost at an end.
To mark their time with us and wish them the best of luck with their future studies, we took the opportunity to speak with one of our placement students in the sales team, to give us an insight of her experience during a Randox placement year.
Meet Kathryn Wilson, Business Placement Sales Executive for Randox Biosciences.
Hi Kathryn, can you tell us a little bit about yourself?
I am a 21-year-old student studying Bsc Equine and Veterinary Bioscience at Aberystwyth University in Wales. In September 2018 I began working in the Biosciences division of Randox Laboratories, specifically working on the release of new molecular technologies for clinical diagnostics. As part of a newly formed sales team, my focus is on the diagnostics market in Ireland.
Why did you want to forge a career in sales?
Whilst studying my bio-veterinary degree my only focus had been on science, so I was keen to broaden my horizons and explore opportunities in a business role for a company involved in the life-sciences industry. Initially, I was tentative of a role in sales, but I knew it would be a good way to develop a broad knowledge of business and the industry, and develop new skills.
Why did you decide to take your placement year with Randox?
Randox was a perfect fit for me, as a global scientific company based in Northern Ireland. I was looking for a placement that would allow me to spend time at home before returning to Wales for university.
I was intrigued by their range of products and diverse market presence in industries such as pharmaceuticals, biotech, research and healthcare. It seemed like a good company to gain an insight into new research in a variety of career sectors.
Describe a typical day as a Business Placement Sales Executive.
My role has evolved as we have moved through the different stages of product development throughout the year. Initially, when I first joined the team, we were in the planning stage. This involved mapping potential contacts and key sites in Ireland, and developing a sales strategy.
As this is a new venture for Randox the role also involved educating the market on our technology and creating awareness in all potential points of sale. This educational aspect of my job involved regular trips and meetings across Ireland, and frequent UK team meetings to discuss market feedback and problem solve. It’s important that we have been able to adapt our sales strategy for the specific healthcare areas -from public to private and point-of-care to large laboratories. Coming into the final month of my placement we are now prepared for product release with confirmed validation studies and initial placements, and significant interest across Ireland.
What are some examples of the tasks and responsibilities of your role?
There has been a range of ongoing tasks throughout the year to facilitate a busy and growing division. I was given the responsibility of forecasting, logging orders and organising meetings, and have been involved in internal decision-making processes alongside management. I have also helped to manage the university contracts in Ireland for our lab equipment, reagents and outsourcing some testing for specific studies.
Before I finish my placement I’m researching the market for upcoming arrays for launch next year, and planning a final trip in Ireland.
What was the most exciting part of your placement with Randox Biosciences?
The opportunity to travel around Ireland and London has been excellent. To date I have participated in over 10 conferences on behalf of Randox. Highlights for me have been corporate hospitality with potential customers at the Randox Health Grand National, and presenting at the first Infectious Disease Forum for Randox, in front of representatives from microbiology sites across Ireland.
I was also trusted to conduct a trip on my own around Donegal and Sligo, coupled with a visit to our Donegal R&D site, Randox Teoranta in Dungloe, to learn about future veterinary arrays in development.
It has been a privilege to be able to work with such a diverse range of people – from the scientists developing the products, to the sales team specialising in markets across the globe. There are so many different career paths here at Randox.
What has been the most challenging aspect of your time at Randox Biosciences?
I have been challenged to quickly adapt to the business environment and gain an in-depth understanding of the wide range of products. I have been pushed outside my comfort zone to discuss with customers, present to the team and take responsibility of the day-to-day tasks.
Knowing the new molecular diagnostics range, infectious disease panels, and competitors in the market well enough to be confident in front of potential customers on my own, has also been a challenge. Hard work at Randox is acknowledged however, and I was awarded runner-up Business Student of the Year.
What is the best thing about Randox and would you recommend this placement to other students?
The best thing about a placement with Randox is that you will be given as many opportunities as you are willing to take. They are very supportive and will push you as much as any other member of the team.
As a non-business student this year has given me a wealth of insight into the workings of a global company, as well as furthering my scientific knowledge and interests in many aspects of the industry.
I would recommend a Randox placement for students who are keen to gain as much experience as possible in a global company focused on new and exciting health research.
What are your goals for the future?
My experience at Randox has given me an excellent insight into the world of business in the biosciences industry, and has prepared me well to build a career in this exciting industry. I think that the experience gained through Randox will be applicable to many life sciences sectors which I would like to explore further.
Although I am not sure what the future may hold, in the shorter term I am looking forward to returning to finish my final year at Aberystwyth.
For more information about Randox Biosciences and what career opportunities we offer please contact firstname.lastname@example.org